Related Experiment Video
Updated: Jul 2, 2025
04:57
Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
10.2K
A Novel Nomogram for Predicting Warfarin-Related Bleeding: A Retrospective Cohort Study
1Department of Cardiology, The Seventh People's Hospital of Zhengzhou, Zhengzhou, China.
Summary
This study developed a new nomogram to predict warfarin-associated bleeding risk in heart disease patients. The model identifies key risk factors, enabling personalized treatment and better patient management for anticoagulant therapy.
Area of Science:
- Cardiology
- Pharmacology
- Medical Informatics
Background:
- Warfarin is a crucial anticoagulant, but bleeding complications frequently lead to treatment discontinuation.
- Existing risk-prediction models for warfarin-associated bleeding are insufficient, highlighting a need for improved tools.
Purpose of the Study:
- To develop and validate a novel risk-prediction nomogram for major and clinically relevant non-major (CRNM) bleeding in patients taking warfarin.
Main Methods:
- A cohort of 280 heart disease outpatients on warfarin was followed for one year.
- Least Absolute Shrinkage and Selection Operator (LASSO) regression identified predictors, with backward stepwise selection refining the model.
- Model performance was assessed using ROC curves, calibration plots, Hosmer-Lemeshow tests, and decision curve analysis (DCA).
Main Results:
- The final nomogram included four predictors: female sex, transient ischemic attack (TIA), time in therapeutic range (TTR), and anemia.
- The model demonstrated acceptable discrimination (AUC = 0.68) and superior performance compared to nine existing scoring systems.
- The nomogram showed good calibration and clinical utility as confirmed by DCA.
Conclusions:
- A validated nomogram for predicting warfarin-related bleeding risk has been developed.
- This tool facilitates rapid risk stratification and supports personalized treatment strategies for warfarin users.
- The nomogram offers a valuable basis for managing anticoagulant therapy and mitigating bleeding complications.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
01:24Disorders of Hemostasis
906
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
906